IL95134A - Method and composition for inhibiting virus replication of HIV in mammalian cells using human CD4 or CD5 antigen monoclonal antibody and pokeweed antiviral protein conjugate - Google Patents

Method and composition for inhibiting virus replication of HIV in mammalian cells using human CD4 or CD5 antigen monoclonal antibody and pokeweed antiviral protein conjugate

Info

Publication number
IL95134A
IL95134A IL9513490A IL9513490A IL95134A IL 95134 A IL95134 A IL 95134A IL 9513490 A IL9513490 A IL 9513490A IL 9513490 A IL9513490 A IL 9513490A IL 95134 A IL95134 A IL 95134A
Authority
IL
Israel
Prior art keywords
pap
hiv
cells
antibody
replication
Prior art date
Application number
IL9513490A
Other languages
English (en)
Other versions
IL95134A0 (en
Original Assignee
Univ Minnesota
Minn And Oncogen Limited Partn
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Minnesota, Minn And Oncogen Limited Partn filed Critical Univ Minnesota
Publication of IL95134A0 publication Critical patent/IL95134A0/xx
Publication of IL95134A publication Critical patent/IL95134A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6849—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a receptor, a cell surface antigen or a cell surface determinant
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • A61K47/6811—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a protein or peptide, e.g. transferrin or bleomycin
    • A61K47/6817—Toxins
    • A61K47/6819—Plant toxins
    • A61K47/6825—Ribosomal inhibitory proteins, i.e. RIP-I or RIP-II, e.g. Pap, gelonin or dianthin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Virology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Toxicology (AREA)
  • Oncology (AREA)
  • Immunology (AREA)
  • Communicable Diseases (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Molecular Biology (AREA)
  • Cell Biology (AREA)
  • Botany (AREA)
  • AIDS & HIV (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
IL9513490A 1989-07-25 1990-07-20 Method and composition for inhibiting virus replication of HIV in mammalian cells using human CD4 or CD5 antigen monoclonal antibody and pokeweed antiviral protein conjugate IL95134A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US38531489A 1989-07-25 1989-07-25
US50352290A 1990-03-30 1990-03-30

Publications (2)

Publication Number Publication Date
IL95134A0 IL95134A0 (en) 1991-06-10
IL95134A true IL95134A (en) 1996-01-31

Family

ID=27010961

Family Applications (1)

Application Number Title Priority Date Filing Date
IL9513490A IL95134A (en) 1989-07-25 1990-07-20 Method and composition for inhibiting virus replication of HIV in mammalian cells using human CD4 or CD5 antigen monoclonal antibody and pokeweed antiviral protein conjugate

Country Status (17)

Country Link
EP (1) EP0441917B1 (de)
JP (1) JP3109678B2 (de)
KR (1) KR920700698A (de)
AT (1) ATE137410T1 (de)
AU (1) AU631674B2 (de)
CA (1) CA2037900C (de)
DE (1) DE69026812T2 (de)
DK (1) DK0441917T3 (de)
ES (1) ES2087158T3 (de)
FI (1) FI911447A0 (de)
GR (1) GR1002180B (de)
IE (1) IE74143B1 (de)
IL (1) IL95134A (de)
NO (1) NO911174L (de)
NZ (1) NZ234607A (de)
PT (1) PT94789B (de)
WO (1) WO1991001145A1 (de)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH0425604U (de) * 1990-06-27 1992-02-28
GB9217124D0 (en) * 1992-08-13 1992-09-23 Antisoma Ltd Medical treatment
US6576236B1 (en) * 1994-07-01 2003-06-10 Dana Farber Cancer Institute Methods for stimulating T cell responses by manipulating a common cytokine receptor γ chain
US5919457A (en) * 1996-01-11 1999-07-06 Regents Of The University Of Minnesota TXU-5/B53-PAP antiviral biotherapeutic agent for the treatment of AIDS
DK2696687T3 (en) 2011-04-12 2017-02-06 Novo Nordisk As Double-acylated GLP-1 derivatives

Also Published As

Publication number Publication date
ATE137410T1 (de) 1996-05-15
AU631674B2 (en) 1992-12-03
KR920700698A (ko) 1992-08-10
IE74143B1 (en) 1997-07-02
FI911447A7 (fi) 1991-03-25
DE69026812T2 (de) 1996-11-28
WO1991001145A1 (en) 1991-02-07
JP3109678B2 (ja) 2000-11-20
PT94789A (pt) 1991-03-20
EP0441917A1 (de) 1991-08-21
NO911174D0 (no) 1991-03-22
PT94789B (pt) 1997-04-30
CA2037900A1 (en) 1991-01-26
CA2037900C (en) 1999-11-16
IE902593A1 (en) 1991-02-27
AU6140590A (en) 1991-02-22
JPH04502625A (ja) 1992-05-14
GR900100550A (el) 1991-12-10
NZ234607A (en) 1992-10-28
IL95134A0 (en) 1991-06-10
FI911447A0 (fi) 1991-03-25
DE69026812D1 (de) 1996-06-05
DK0441917T3 (da) 1996-09-16
GR1002180B (en) 1996-03-11
EP0441917B1 (de) 1996-05-01
ES2087158T3 (es) 1996-07-16
NO911174L (no) 1991-05-24

Similar Documents

Publication Publication Date Title
US4869903A (en) Method of selectively inhibiting HIV
US6372217B1 (en) Methods for the treatment of CD7+ viral infection with TXU-7-PAP
DE3855869T2 (de) Verfahren und Zubereitungen für die Verwendung von HIV-env-Polypeptiden und Antikörpern
US5919457A (en) TXU-5/B53-PAP antiviral biotherapeutic agent for the treatment of AIDS
WO1997025071A9 (en) Immunoconjugate for the treatment of aids
EP0441917B1 (de) Konjugate von "pokeweed" antiviralem protein und monoklonalen antikörpern
WO1993017038A1 (en) Methods of treating diabetes
CA2209767A1 (en) Biotherapy of cancer by targeting tp-3/p80
Kim et al. Immunoconjugates that neutralize HIV virions kill T cells infected with diverse strains of HIV-1.
Barnett et al. Antiviral immunotoxins: antibody-mediated delivery of gelonin inhibits Pichinde virus replication in vitro
EP1144010B1 (de) Vorbeugung der kronischen transplantat-abstossung durch eine kombination von immuntoxinen und kostimulationblocker
EP0381763B1 (de) Mit toxin modifizierter antikörper
AU738749B2 (en) Targeted cytotoxic cells
Izquierdo et al. Selective T cell subset depletion with anti-CD4 and anti-CD8 intact ricin immunotoxins
Gallagher et al. Monoclonal antibody-ricin A chain conjugates (immunotoxins): potential therapeutic agents for human colon carcinoma

Legal Events

Date Code Title Description
FF Patent granted
KB Patent renewed
KB Patent renewed
MM9K Patent not in force due to non-payment of renewal fees